Known human carcinogens, environmental hazards. Benzene, carbon tetrachloride, 1,2-dichloroethane. Should not be used in pharmaceutical manufacturing.

Non-genotoxic animal carcinogens or possible causative agents of irreversible toxicity. Use should be limited. DCM, chloroform, NMP, methanol, toluene.

Lower human health risk. Acceptable without limits below 50 mg/day (unless greater amounts present). Ethanol, ethyl acetate, 2-MeTHF, CPME, acetone.

DCM remains fully liquid at −96.7 °C, making it the only practical solvent for reactions requiring dry ice/acetone (−78 °C) or liquid nitrogen bath conditions. Asymmetric reactions relying on chiral auxiliaries or chiral catalysts - Sharpless epoxidation workups, CBS reductions, Evans oxazolidinone reactions - routinely specify DCM as the solvent.

Key reactions: Swern oxidation, asymmetric Diels-Alder, chiral amine-catalysed aldol

Friedel-Crafts acylation (AlCl₃ catalyst), Mukaiyama aldol (TiCl₄ or BF₃·OEt₂), and other Lewis acid-catalysed transformations require a solvent that coordinates weakly with the Lewis acid. DCM's weak donor ability makes it ideal - stronger donor solvents like THF or DMF would deactivate the catalyst.

Key reactions: Acylation, Mukaiyama aldol, Diels-Alder with Lewis acid catalysis

DCM is the dominant solvent in solution-phase peptide synthesis and for installation/removal of Boc (tert-butyloxycarbonyl) and Fmoc protecting groups. Its ability to dissolve both amino acid derivatives and coupling reagents (HATU, HBTU, DCC) - while being compatible with base and acid conditions - is difficult to replicate.

Key reactions: Boc deprotection (TFA/DCM), amide coupling (EDC/HATU), SPPS washing

Swern oxidation (oxalyl chloride / DMSO), Dess-Martin periodinane (DMP) oxidation, and mCPBA epoxidation all specify DCM as the standard solvent. These reactions are typically run cold (−78 to 0 °C) and benefit from DCM's stability toward the oxidising reagents employed.

Key reactions: Swern, Dess-Martin, mCPBA epoxidation, Rubottom oxidation

Grubbs catalyst-mediated ring-closing metathesis (RCM) and cross-metathesis (CM) are routinely run in DCM, which dissolves both substrate and catalyst and provides an inert medium with appropriate polarity. DCM is specified in the majority of published Grubbs catalyst procedures.

Key reactions: RCM, ADMET, CM with Grubbs 1st and 2nd generation catalysts

DIBAL-H (diisobutylaluminium hydride) reductions of esters to aldehydes, CBS (Corey-Bakshi-Shibata) ketone reductions, and Mitsunobu reactions all frequently use DCM. Its compatibility with organometallic hydride reagents at low temperature is a key enabling feature.

Key reactions: DIBAL-H reduction, CBS reduction, Mitsunobu, Wittig

DCM is the standard industrial solvent for isolating alkaloids (morphine, codeine, quinine, caffeine, berberine) from plant material. After acidification of the aqueous plant extract (to protonate the alkaloid), basification to free-base form, and then DCM extraction, alkaloids partition selectively into the organic phase - leaving behind most polar plant pigments, sugars, and salts.

Commercial caffeine extraction from coffee and tea uses DCM in a selective partition process. Hot water extracts caffeine from the plant material; the aqueous caffeine solution is then contacted with DCM, which selectively absorbs caffeine (D ≈ 8–10 between DCM and water) while most polar phenolic compounds remain in the aqueous phase. The DCM caffeine solution is then distilled to recover pure caffeine.

Lipophilic terpenoids - sesquiterpenes, diterpenes, triterpenes - and essential oil constituents extracted from herbs, flowers, and wood are efficiently recovered using DCM. Unlike steam distillation (which may degrade thermolabile terpenoids), DCM cold extraction preserves the full chemical profile of thermally sensitive compounds.

Antibiotics, statins, immunosuppressants, and other fermentation-derived APIs are commonly extracted from clarified fermentation broths using DCM in continuous countercurrent extraction systems. DCM's density advantage allows simple phase separation even in high-salt, viscous fermentation matrices where lighter solvents form troublesome emulsions.

Q1: What is the ICH Q3C residual solvent limit for DCM in pharmaceutical products?

Under ICH Q3C (Revision 10), DCM is a Class 2 solvent with a Permitted Daily Exposure (PDE) of 6.0 mg/day. Assuming a maximum daily dose of 10 g of drug product, the concentration limit in the finished product is 600 ppm. This limit applies across the FDA (US), EMA (EU), PMDA (Japan), and NMPA (China) as all are ICH member organisations that have adopted Q3C. For lower daily doses, the concentration limit may be proportionally higher - consult the Q3C guideline's dose-based calculation table.

Q2: Why is chloroform content the most critical impurity to control in pharma-grade DCM?

Chloroform (CHCl₃) is a close structural relative of DCM and the most likely process impurity from DCM production (over-chlorination of methane). In ICH Q3C, chloroform is also a Class 2 solvent with a PDE of just 0.6 mg/day - ten times more restrictive than DCM's 6.0 mg/day. If technical-grade DCM containing 200 ppm chloroform is used in a pharmaceutical process, the residual chloroform in the finished drug could approach or exceed its own ICH limit even when DCM itself is within specification. This is why pharma-grade DCM specifies chloroform ≤10 ppm - to ensure the combined residual burden from both solvents remains within limits.

Q3: Can DCM be used in the final step of pharmaceutical synthesis?

Yes - but use in final or near-final synthesis steps increases the residual solvent control burden significantly, as less processing follows to further reduce the DCM level. If DCM is used in the final crystallisation or last purification step, the manufacturer must demonstrate that the residual level in the final API is ≤600 ppm (or the applicable dose-based limit) through validated GC headspace analysis per USP <467>. Many manufacturers prefer to reserve DCM for earlier synthesis steps where subsequent aqueous workups, distillation, or drying provide additional removal opportunities before final product testing.

Q4: Does DCM react with any common pharmaceutical reagents?

DCM is remarkably inert to most reagents used in pharmaceutical synthesis, which is a primary reason for its widespread use. However, there are important exceptions: (1) Strong bases (n-BuLi, NaH, NaOH above ~50 °C) can deprotonate DCM to form dichloromethyl anion or carbenoid species - avoid using DCM with highly reactive organolithium or organosodium reagents. (2) Strong Lewis acids at elevated temperatures can promote Friedel-Crafts type side reactions. (3) Primary amines can react slowly with DCM over time (Menschutkin-type reaction) - this is generally not a problem at the timescales of typical reactions but is worth considering for storage of amine-DCM mixtures.

Q5: What documentation does a Chinese DCM supplier need to provide for pharmaceutical customers?

For pharmaceutical use, a Chinese DCM supplier should provide: (1) Batch-specific Certificate of Analysis (COA) with all parameters listed in the pharma grade specification table above; (2) SDS in the buyer's language, compliant with GHS and (for EU) REACH Annex II; (3) GMP compliance statement - at minimum, a declaration that the material is manufactured and handled under a documented quality management system; (4) ICH Q3C Class 2 information package - confirming the solvent classification and available test data; (5) REACH registration number (for EU buyers - if the Chinese supplier's European partner is the Only Representative); (6) Compliant DGD (UN 1593) for each shipment. Discuss these requirements explicitly before placing your first order.

Q6: Is DCM extraction of natural products considered food-safe?

It depends on the end product and jurisdiction. For direct food applications (decaffeination), DCM is permitted by FDA (10 ppm residual limit in coffee) and EU regulations (2 ppm). For botanical extracts used in dietary supplements or nutraceuticals, the regulatory situation is more complex - some jurisdictions permit DCM extraction with residual limits; others require that the final product contain no detectable DCM. For pharmaceutical natural products (herbal medicinal products), ICH Q3C Class 2 limits apply: 600 ppm in the final product. Always confirm the applicable residual limit with your regulatory affairs team before selecting DCM as the extraction solvent for a new product.